Evidence map›Paper›PMID 37566304›Full record

ArticleOphthalmology and therapy2023

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.

Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Junko Morii, Eriko Kunikane, Taiji Sakamoto

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Yasuo YanagiDepartment of Ophthalmology and Microtechnology, Yokohama City University, Kanagawa, Japan. yanagi-tky@umin.ac.jp.
Kanji TakahashiDepartment of Ophthalmology, Kansai Medical University, Osaka, Japan.
Tomohiro IidaDepartment of Ophthalmology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Fumi GomiDepartment of Ophthalmology, Hyogo Medical University, Hyogo, Japan.
Junko MoriiIQVIA Solutions Japan, K.K., Tokyo, Japan.
Eriko KunikaneSenju Pharmaceutical Co., Ltd., Osaka, Japan.
Taiji SakamotoDepartment of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Hyogo University · JPKagoshima University · JPKansai Medical University · JPSenju Pharmaceutical (Japan) · JPTokyo Women's Medical University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37566304
PMCPMC10442042
OpenAlexW4385751410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.